Androgen Deprivation Therapy in Prostate Cancer - Current Status in M1 Patients
Authors:
- Nicolas MottetNMNicolas Mottet
- 16 November 2015
- journal article
- review article
- Published by S. Karger AG in Oncology Research and Treatment
- Vol. 38 (12) , 646-652
Abstract
Androgen deprivation therapy is the cornerstone treatment for metastatic prostate cancer. It can be done either surgically or medically. Luteinizing hormone-releasing hormone agonists and antagonist are the most effective drugs, with different side effects and modes of action, but no clear efficacy differences. Adding a non-steroidal antiandrogen adds a marginal benefit but also significant side effects and costs. Non-steroidal antiandrogens should not be used as monotherapy. In most patients with metastases, immediate castration is the standard of care. The intermittent modality is apparently non-inferior to the continuous one, with some other benefits. Upfront chemotherapy added to castration should be considered as the new standard of care in many metastatic patients. Castration leads to many adverse effects, some potentially life-threatening such as cardiovascular side effects.Keywords
This publication has 40 references indexed in Scilit:
- Treatment of Prostate Cancer With Intermittent Versus Continuous Androgen Deprivation: A Systematic Review of Randomized TrialsJournal of Clinical Oncology, 2013
- Incomplete testosterone suppression with luteinizing hormone‐releasing hormone agonists: does it happen and does it matter?BJU International, 2012
- Contemporary Role of Androgen Deprivation Therapy for Prostate CancerEuropean Urology, 2012
- A Phase III Extension Trial With a 1-Arm Crossover From Leuprolide to Degarelix: Comparison of Gonadotropin-Releasing Hormone Agonist and Antagonist Effect on Prostate CancerJournal of Urology, 2011
- Diabetes and Cardiovascular Disease During Androgen Deprivation Therapy: Observational Study of Veterans With Prostate CancerJNCI: Journal of the National Cancer Institute, 2009
- The Nonsteroidal Effects of Diethylstilbestrol: The Rationale for Androgen Deprivation Therapy Without Estrogen Deprivation in the Treatment of Prostate CancerJournal of Urology, 2003
- Metastatic Carcinoma of the Prostate: Identifying Prognostic Groups Using Recursive PartitioningJournal of Urology, 2003
- Studies on Prostatic CancerJournal of Urology, 2002
- Early versus deferred androgen suppression in the treatment of advanced prostatic cancerCochrane Database of Systematic Reviews, 2001
- Why phase III trials of maximal androgen blockade versus castration in M1 prostate cancer rarely show statistically significant differences*The Prostate, 2001